![]() |
Volumn 13, Issue 5, 2007, Pages 554-556
|
Should the development of new antibiotics be a public health priority?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIBIOTIC AGENT;
CEFEPIME;
CEFOXITIN;
CEFTOBIPROLE;
CEFTRIAXONE;
CEPHALOSPORIN;
COTRIMOXAZOLE;
DAPTOMYCIN;
DOXYCYCLINE;
ERTAPENEM;
FUSIDIC ACID;
GENERIC DRUG;
LINEZOLID;
MEROPENEM;
MINOCYCLINE;
NEW DRUG;
NON PRESCRIPTION DRUG;
PENICILLIN G;
PIPERACILLIN;
RIFAMPICIN;
TAZOBACTAM;
TIGECYCLINE;
COMMUNITY ACQUIRED PNEUMONIA;
COST BENEFIT ANALYSIS;
DIAGNOSTIC ACCURACY;
DRUG BIOAVAILABILITY;
DRUG COST;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG MANUFACTURE;
DRUG POTENCY;
DRUG USE;
ECONOMIC ASPECT;
EDITORIAL;
EUROPE;
HEALTH CARE POLICY;
HOSPITAL;
HUMAN;
MEDICAL CARE;
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;
PRESCRIPTION;
PSEUDOMONAS;
PUBLIC HEALTH;
STAPHYLOCOCCUS INFECTION;
ANTI-BACTERIAL AGENTS;
BIOMEDICAL RESEARCH;
DRUG RESISTANCE, MICROBIAL;
DRUG UTILIZATION;
HEALTH PRIORITIES;
HUMANS;
PUBLIC HEALTH;
|
EID: 34548421961
PISSN: 10705295
EISSN: 15317072
Source Type: Journal
DOI: 10.1097/MCC.0b013e3282efc3af Document Type: Editorial |
Times cited : (3)
|
References (13)
|